Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis

BACKGROUND: Biologic disease modifying agents (bDMARDs) are an integral part of rheumatoid arthritis treatment guidelines but are associated with significant cost in the US. We present the trends in total spending and unit cost of conventional DMARDs (cDMARDs) as compared to bDMARDs in Medicare prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalal, Deepan S., Zhang, Tingting, Shireman, Theresa I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453205/
https://www.ncbi.nlm.nih.gov/pubmed/32896694
http://dx.doi.org/10.1016/j.semarthrit.2020.08.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453205/
https://www.ncbi.nlm.nih.gov/pubmed/32896694
http://dx.doi.org/10.1016/j.semarthrit.2020.08.002

Ejemplares similares